Pretransplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of Alemtuzumab

Rao, 2005, Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen, Blood, 105, 879, 10.1182/blood-2004-03-0960 Shenoy, 2005, A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders, Bone Marrow Transplant, 35, 345, 10.1038/sj.bmt.1704795 Cooper, 2006, Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis, Blood, 107, 1233, 10.1182/blood-2005-05-1819 Bhatla, 2008, Reduced-intensity conditioning is effective and safe for transplantation of patients with Shwachman-Diamond syndrome, Bone Marrow Transplant, 42, 159, 10.1038/bmt.2008.151 Hansen, 2008, Allogeneic hematopoietic cell transplantation (HCT) in Hurler's syndrome using a reduced intensity preparative regimen, Bone Marrow Transplant, 41, 349, 10.1038/sj.bmt.1705926 Marsh, 2015, Biol Blood Marrow Transplant, 21, 1460, 10.1016/j.bbmt.2015.04.009 Gungor, 2014, Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study, Lancet, 383, 436, 10.1016/S0140-6736(13)62069-3 Law, 2012, Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution, Biol Blood Marrow Transplant, 18, 1656, 10.1016/j.bbmt.2012.05.006 Rebello, 2001, Pharmacokinetics of CAMPATH-1H in BMT patients, Cytotherapy, 3, 261, 10.1080/146532401317070899 Mould, 2007, Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response, Br J Clin Pharmacol, 64, 278, 10.1111/j.1365-2125.2007.02914.x Patel, 2016, Comparison of subcutaneous versus intravenous alemtuzumab for graft-versus-host disease prophylaxis with fludarabine/melphalan-based conditioning in matched unrelated donor allogeneic stem cell transplantation, Biol Blood Marrow Transplant, 22, 456, 10.1016/j.bbmt.2015.10.022 Marsh, 2013, An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis, Biol Blood Marrow Transplant, 19, 1625, 10.1016/j.bbmt.2013.09.001 Chakraverty, 2010, Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution, Blood, 116, 3080, 10.1182/blood-2010-05-286856 Lane, 2014, Low-dose serotherapy improves early immune reconstitution after cord blood transplantation for primary immunodeficiencies, Biol Blood Marrow Transplant, 20, 243, 10.1016/j.bbmt.2013.11.005 Gartner, 2013, Lowering the alemtuzumab dose in reduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recovery, Cytotherapy, 15, 1237, 10.1016/j.jcyt.2013.05.016 Marsh, 2016, Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT, Blood, 127, 503, 10.1182/blood-2015-07-659672 Rebello, 2002, Pharmacokinetics of CAMPATH-1H: assay development and validation, J Immunol Methods, 260, 285, 10.1016/S0022-1759(01)00556-7 Elsner, 1996, Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils, Blood, 88, 4684, 10.1182/blood.V88.12.4684.bloodjournal88124684 Ambrose, 2009, Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab, Blood, 114, 3052, 10.1182/blood-2009-02-203075 Hu, 2009, Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model, Immunology, 128, 260, 10.1111/j.1365-2567.2009.03115.x Marsh, 2016, Alemtuzumab levels impact acute GVHD, mixed chimerism, & lymphocyte recovery following alemtuzumab, fludarabine & melphalan RIC HCT, Blood, 127, 503, 10.1182/blood-2015-07-659672 Admiraal, 2015, Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis, Lancet Haematol, 2, e194, 10.1016/S2352-3026(15)00045-9